Compare BRR & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRR | CCCC |
|---|---|---|
| Founded | 2024 | 2015 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.1M | 185.1M |
| IPO Year | N/A | 2020 |
| Metric | BRR | CCCC |
|---|---|---|
| Price | $2.01 | $2.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 915.7K | ★ 2.4M |
| Earning Date | 06-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $1.77 | $1.20 |
| 52 Week High | $10.51 | $3.82 |
| Indicator | BRR | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 42.60 | 55.72 |
| Support Level | $1.83 | $2.30 |
| Resistance Level | $3.01 | $3.82 |
| Average True Range (ATR) | 0.18 | 0.23 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 54.76 | 82.64 |
ProCap Financial Inc is focused on Bitcoin-focused media products and Bitcoin holdings. The Company typically provides advertising and marketing services through weekly digital media placements, including audio and social media advertisements. The Company offers media products to help independent investors understand financial markets, current events, and technology advancements. These media products include social media accounts, email newsletters, and audio or video content. The Company also added strategies related to the use of AI and automation to support the development and delivery of financial products and services.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.